These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 22045404)

  • 1. Diagnostic and prognostic molecular markers in hepatocellular carcinoma.
    Mínguez B; Lachenmayer A
    Dis Markers; 2011; 31(3):181-90. PubMed ID: 22045404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
    Villanueva A; Minguez B; Forner A; Reig M; Llovet JM
    Annu Rev Med; 2010; 61():317-28. PubMed ID: 20059340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
    Kudo M
    J Gastroenterol Hepatol; 2010 Mar; 25(3):439-52. PubMed ID: 20370723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
    Ozenne V; Paradis V; Pernot S; Castelnau C; Vullierme MP; Bouattour M; Valla D; Farges O; Degos F
    Eur J Gastroenterol Hepatol; 2010 Sep; 22(9):1106-10. PubMed ID: 20300004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy.
    Pompili M; Rapaccini GL; Covino M; Pignataro G; Caturelli E; Siena DA; Villani MR; Cedrone A; Gasbarrini G
    Cancer; 2001 Jul; 92(1):126-35. PubMed ID: 11443618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
    Llovet JM; Peña CE; Lathia CD; Shan M; Meinhardt G; Bruix J;
    Clin Cancer Res; 2012 Apr; 18(8):2290-300. PubMed ID: 22374331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
    Vagefi PA; Hirose R
    J Gastrointest Cancer; 2010 Dec; 41(4):217-20. PubMed ID: 20443078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
    Raoul JL; Bruix J; Greten TF; Sherman M; Mazzaferro V; Hilgard P; Scherubl H; Scheulen ME; Germanidis G; Dominguez S; Ricci S; Nadel A; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 May; 56(5):1080-1088. PubMed ID: 22245896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular targeted therapies in hepatocellular carcinoma.
    Llovet JM; Bruix J
    Hepatology; 2008 Oct; 48(4):1312-27. PubMed ID: 18821591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib in advanced hepatocellular carcinoma.
    Copur MS
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065701
    [No Abstract]   [Full Text] [Related]  

  • 11. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    Zhu AX; Clark JW
    Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
    [No Abstract]   [Full Text] [Related]  

  • 13. Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.
    Xu Y; Chenna V; Hu C; Sun HX; Khan M; Bai H; Yang XR; Zhu QF; Sun YF; Maitra A; Fan J; Anders RA
    Clin Cancer Res; 2012 Mar; 18(5):1291-302. PubMed ID: 21868763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
    Gnoni A; Santini D; Scartozzi M; Russo A; Licchetta A; Palmieri V; Lupo L; Faloppi L; Palasciano G; Memeo V; Angarano G; Brunetti O; Guarini A; Pisconti S; Lorusso V; Silvestris N
    Expert Opin Ther Targets; 2015; 19(12):1623-35. PubMed ID: 26212068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of methylation-driven genes and pretreatment prognostic factors in patients with hepatocellular carcinoma.
    He D; Liao S; Cai L; Huang W; Xie X; You M
    BMC Cancer; 2021 May; 21(1):599. PubMed ID: 34034705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
    Lee JH; Park JY; Kim DY; Ahn SH; Han KH; Seo HJ; Lee JD; Choi HJ
    Liver Int; 2011 Sep; 31(8):1144-9. PubMed ID: 21745288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
    Horger M; Lauer UM; Schraml C; Berg CP; Koppenhöfer U; Claussen CD; Gregor M; Bitzer M
    BMC Cancer; 2009 Jun; 9():208. PubMed ID: 19558720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
    Sacco R; Bargellini I; Ginanni B; Bertini M; Faggioni L; Federici G; Romano A; Bertoni M; Metrangolo S; Altomare E; Parisi G; Tumino E; Scaramuzzino A; Bresci G; Bartolozzi C
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):869-75. PubMed ID: 22845401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.